Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Collections
    • Subjects A-Z
    • Residents & Fellows
    • Patient Pages
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Collections
    • Subjects A-Z
    • Residents & Fellows
    • Patient Pages
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

January 09, 2018; 90 (2) Article

Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases

Divyanshu Dubey, Vanda A. Lennon, Avi Gadoth, Sean J. Pittock, Eoin P. Flanagan, John E. Schmeling, Andrew McKeon and Christopher J. Klein
First published December 8, 2017, DOI: https://doi.org/10.1212/WNL.0000000000004803
Divyanshu Dubey
From the Departments of Neurology (D.D., A.G., S.J.P., E.P.F., A.M., C.J.K.) and Laboratory Medicine and Pathology (V.A.L., S.J.P., E.P.F., J.E.S., A.M., C.J.K.), Mayo Clinic, Rochester, MN.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanda A. Lennon
From the Departments of Neurology (D.D., A.G., S.J.P., E.P.F., A.M., C.J.K.) and Laboratory Medicine and Pathology (V.A.L., S.J.P., E.P.F., J.E.S., A.M., C.J.K.), Mayo Clinic, Rochester, MN.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Avi Gadoth
From the Departments of Neurology (D.D., A.G., S.J.P., E.P.F., A.M., C.J.K.) and Laboratory Medicine and Pathology (V.A.L., S.J.P., E.P.F., J.E.S., A.M., C.J.K.), Mayo Clinic, Rochester, MN.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean J. Pittock
From the Departments of Neurology (D.D., A.G., S.J.P., E.P.F., A.M., C.J.K.) and Laboratory Medicine and Pathology (V.A.L., S.J.P., E.P.F., J.E.S., A.M., C.J.K.), Mayo Clinic, Rochester, MN.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eoin P. Flanagan
From the Departments of Neurology (D.D., A.G., S.J.P., E.P.F., A.M., C.J.K.) and Laboratory Medicine and Pathology (V.A.L., S.J.P., E.P.F., J.E.S., A.M., C.J.K.), Mayo Clinic, Rochester, MN.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John E. Schmeling
From the Departments of Neurology (D.D., A.G., S.J.P., E.P.F., A.M., C.J.K.) and Laboratory Medicine and Pathology (V.A.L., S.J.P., E.P.F., J.E.S., A.M., C.J.K.), Mayo Clinic, Rochester, MN.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew McKeon
From the Departments of Neurology (D.D., A.G., S.J.P., E.P.F., A.M., C.J.K.) and Laboratory Medicine and Pathology (V.A.L., S.J.P., E.P.F., J.E.S., A.M., C.J.K.), Mayo Clinic, Rochester, MN.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Klein
From the Departments of Neurology (D.D., A.G., S.J.P., E.P.F., A.M., C.J.K.) and Laboratory Medicine and Pathology (V.A.L., S.J.P., E.P.F., J.E.S., A.M., C.J.K.), Mayo Clinic, Rochester, MN.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PDF
Citation
Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases
Divyanshu Dubey, Vanda A. Lennon, Avi Gadoth, Sean J. Pittock, Eoin P. Flanagan, John E. Schmeling, Andrew McKeon, Christopher J. Klein
Neurology Jan 2018, 90 (2) e103-e110; DOI: 10.1212/WNL.0000000000004803

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Comment

Downloads
187

Share

  • Article
  • Figures & Data
  • Info
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective To establish the phenotype and clinical outcomes of collapsin response-mediator protein-5 (CRMP5) autoimmune neuropathy in comparison with anti-neuronal nuclear antibody type 1 (ANNA1)–immunoglobulin G (IgG) neuropathy.

Methods Patients with CRMP5-IgG and/or ANNA1-IgGs were identified in our service-line testing, and medical records were reviewed.

Results One hundred five patients with CRMP5-IgG neuropathy (88% smokers; 69% having cancer, most commonly small cell lung cancer [75%]) were identified and compared to 51 patients with ANNA1-IgG neuropathy, 27 with coexisting CRMP5-IgG. Patients with CRMP5 had painful axonal polyradiculoneuropathy (65%), mostly asymmetric onset (84%), with neuropathy predating cancer diagnosis by 185 days (range 60–540 days). Most cases (79%) had moderate to severe neuropathic pain, all on neuropathic medications (median 2, range 1–4), opioids in 39%. Nerve biopsies (n = 2) showed microvascular inflammation with axonal degeneration. Compared to ANNA1 alone, CRMP5 neuropathy has a higher prevalence of pain (79% vs 46%, p = 0.008), asymmetric polyradiculoneuropathy (54% vs 12%, p < 0.001), and inflammatory spinal fluids (elevated CSF protein or nucleated cell count 92% vs 60%, p = 0.022). Cerebellar ataxia (21%), myelopathy (19%), and optic neuritis and/or retinitis (11%) were common neurologic accompaniments. CRMP5 cases had significant pain reduction by immunotherapy (p < 0.001). Specifically, high-dose corticosteroid administration was associated with improvement/stabilization in neuropathy impairment scores (p = 0.012) (Class IV). Patients with CRMP5 had better 5-year survival than patients with ANNA1 (67% vs 32%, p = 0.012).

Conclusion Painful axonal asymmetric polyradiculoneuropathy is established as the major CRMP5 autoimmune neuropathy presentation and is distinguishable from other paraneoplastic neuropathies, including by ANNA1 autoimmunity. Patients with this phenotype should be prompted for CRMP5-IgG testing to assist in early cancer diagnosis.

Glossary

AMPA=
a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid;
ANNA1=
anti-neuronal nuclear antibody type 1;
CASPR=
contactin-associated protein-2;
CRMP5=
collapsin response-mediator protein-5;
IgG=
immunoglobulin G;
LGI1=
leucine-rich glioma-inactivated-1;
mRS=
modified Rankin Scale;
NIS=
neuropathy impairment score;
PCA=
Purkinje-cell cytoplasmic;
VGCC=
voltage gated calcium channel;
VGKC=
voltage-gated potassium channel complex

Footnotes

  • Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Received June 4, 2017.
  • Accepted in final form September 26, 2017.
  • Copyright © 2017 American Academy of Neurology
View Full Text

AAN Members: Sign in with your AAN member credentials (e-mail or 6-digit Member ID number)

Non-AAN Member subscribers: Sign in with subscriber credentials

Log in using your username and password

Forgot your user name or password?

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All contributors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
Publication Date - String

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Methods
    • Results
    • Discussion
    • Author contributions
    • Study funding
    • Disclosure
    • Footnotes
    • References
  • Figures & Data
  • Info

Related Articles

  • No related articles found.

Topics Discussed

  • Autoimmune diseases
  • Neuropathic pain
  • Peripheral neuropathy
  • Paraneoplastic syndrome

Alert Me

  • Alert me when this article is cited
  • Alert me if a correction is posted
  • Alert me when eletters are published
Neurology: 90 (16)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Submit a Peer Review
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Neurology Now
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2018 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise